Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18790657 | CAPSID VARIANTS AND METHODS OF USING THE SAME | July 2024 | April 2025 | Allow | 8 | 1 | 0 | No | No |
| 18788938 | CAPSID VARIANTS AND METHODS OF USING THE SAME | July 2024 | April 2025 | Allow | 8 | 1 | 0 | No | No |
| 18537448 | PREFUSION PIV F IMMUNOGENS AND THEIR USE | December 2023 | May 2025 | Allow | 17 | 1 | 1 | No | No |
| 18521590 | MATERIALS AND METHODS FOR TREATING CANCER | November 2023 | May 2025 | Allow | 18 | 1 | 1 | No | No |
| 18517808 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | November 2023 | September 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18471955 | BIVALENT DENGUE/HEPATITUS B VACCINES | September 2023 | April 2025 | Allow | 18 | 2 | 1 | No | No |
| 18463609 | IMMUNITY-INDUCING AGENT AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | September 2023 | October 2024 | Allow | 13 | 0 | 1 | No | No |
| 18455787 | Conformationally Specific Viral Immunogens | August 2023 | September 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18453078 | SIMIAN ADENOVIRAL VECTORS WITH TWO EXPRESSION CASSETTES | August 2023 | August 2024 | Allow | 12 | 0 | 1 | No | No |
| 18200421 | EXPRESSION SYSTEMS | May 2023 | November 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18311056 | VACCINES AGAINST CORONAVIRUS AND METHODS OF USE | May 2023 | February 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18310066 | Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus | May 2023 | October 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 18299676 | VACCINATION IN NEWBORNS AND INFANTS | April 2023 | April 2025 | Allow | 24 | 1 | 1 | No | No |
| 18113776 | NON-PSYCHOACTIVE CANNABINOIDS AS ADJUVANTS TO ENHANCE MUCOSAL IMMUNITY | February 2023 | June 2025 | Abandon | 28 | 1 | 1 | No | No |
| 18172741 | Anti-Inflammatory Polypeptides | February 2023 | April 2025 | Allow | 26 | 1 | 0 | No | No |
| 18150430 | AAV CHIMERAS | January 2023 | July 2024 | Allow | 19 | 1 | 1 | No | No |
| 18074220 | INFLUENZA B VIRUS MUTANTS AND USES THEREFOR | December 2022 | April 2025 | Allow | 29 | 1 | 1 | No | No |
| 18059269 | METHODS OF PACKAGING MULTIPLE ADENO-ASSOCIATED VIRUS VECTORS | November 2022 | June 2025 | Allow | 30 | 1 | 0 | No | No |
| 17931215 | METHODS AND COMPOSITIONS FOR STIMULATING IMMUNE RESPONSE | September 2022 | August 2024 | Allow | 23 | 1 | 1 | No | No |
| 17818610 | DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF | August 2022 | May 2025 | Abandon | 33 | 1 | 1 | No | No |
| 17816788 | FORMULATIONS FOR SMALL INTESTINAL DELIVERY OF RSV AND NOROVIRUS ANTIGENS | August 2022 | August 2024 | Allow | 24 | 1 | 1 | No | No |
| 17750896 | TREATMENT OF INSECT BITE HYPERSENSITIVITY | May 2022 | October 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17747713 | IMMUNOGENIC COMPOSITIONS AGAINST INFLUENZA | May 2022 | January 2025 | Allow | 32 | 1 | 1 | No | No |
| 17754877 | Vaccine Product | April 2022 | February 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17626288 | ENGINEERED VACCINIA VIRUS | January 2022 | September 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17544418 | AAV PRODUCTION USING SUSPENSION ADAPTED CELLS | December 2021 | November 2024 | Abandon | 35 | 2 | 1 | No | No |
| 17530103 | TREATMENT OF PRURITUS IN HORSES | November 2021 | July 2024 | Allow | 32 | 1 | 1 | Yes | No |
| 17496250 | ANTIBODIES THAT TARGET HIV GP120 AND METHODS OF USE | October 2021 | March 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17408104 | METHODS OF PREDICTING ANCESTRAL VIRUS SEQUENCES AND USES THEREOF | August 2021 | March 2025 | Allow | 42 | 3 | 1 | No | No |
| 17402973 | USE OF VISTA AGONISTS AND ANTAGONISTS TO SUPPRESS OR ENHANCE HUMORAL IMMUNITY | August 2021 | May 2025 | Abandon | 45 | 2 | 1 | No | No |
| 17374399 | VACCINE AGAINST INFECTIOUS BRONCHITIS | July 2021 | October 2024 | Allow | 39 | 2 | 1 | No | No |
| 17415606 | MODIFIED ORTHOPOXVIRUS VECTORS | June 2021 | August 2025 | Abandon | 50 | 0 | 1 | No | No |
| 17333052 | VACCINE COMPOSITION FOR PREVENTING RABIES, AND PREPARATION METHOD THEREOF | May 2021 | March 2025 | Allow | 46 | 2 | 1 | No | No |
| 17306884 | METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY | May 2021 | March 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17227527 | ADENO-ASSOCIATED VIRUS PURIFICATION METHODS | April 2021 | October 2024 | Allow | 43 | 3 | 1 | No | No |
| 17216660 | METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY | March 2021 | April 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17212051 | STIMULATION OF AN IMMUNE RESPONSE BY ENANTIOMERS OF CATIONIC LIPIDS | March 2021 | February 2025 | Abandon | 46 | 4 | 1 | No | No |
| 17053733 | ADENO-ASSOCIATED VIRUS (AAV) DELIVERY OF ANTI-FAM19A5 ANTIBODIES | November 2020 | September 2024 | Allow | 46 | 3 | 1 | No | No |
| 17051296 | LENTIVIRAL-BASED VECTORS AND RELATED SYSTEMS AND METHODS FOR EUKARYOTIC GENE EDITING | October 2020 | April 2025 | Allow | 53 | 2 | 1 | No | No |
| 17038031 | LENTIVIRAL VECTOR FORMULATIONS | September 2020 | April 2025 | Allow | 55 | 5 | 1 | No | Yes |
| 16978177 | ENGINEERED VEGF VARIANTS FOR RETINAL NEUROPROTECTION, PROMOTION OF AXON GROWTH AND AXON REGENERATION | September 2020 | May 2025 | Allow | 56 | 2 | 1 | Yes | No |
| 16648922 | A GENE THERAPY STRATEGY TO RESTORE ELECTRICAL AND CARDIAC FUNCTION, AND CARDIAC STRUCTURE, IN ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY | March 2020 | December 2023 | Allow | 45 | 2 | 1 | No | No |
| 16617805 | A METHOD TO CREATE PERSONALIZED CANCER VACCINES | November 2019 | February 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16614441 | RECOMBINANT ONCOLYTIC VIRUS | November 2019 | February 2025 | Allow | 60 | 5 | 1 | No | No |
| 16604818 | METHODS OF CD40 AND TOLL LIKE RECEPTOR IMMUNE ACTIVATION | October 2019 | August 2024 | Allow | 58 | 4 | 1 | No | No |
| 16480939 | B-CELL ENGINEERING | July 2019 | April 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16481010 | PORCINE CORONAVIRUS VACCINES | July 2019 | June 2024 | Allow | 58 | 4 | 1 | Yes | No |
| 16360278 | PARTICULATE VACCINE FORMULATIONS | March 2019 | May 2025 | Abandon | 60 | 7 | 1 | Yes | Yes |
| 16096673 | RELATIVE POTENCY ASSAY FOR VIRAL VECTOR ENCODING ISOMEROHYDROLASES | October 2018 | March 2025 | Allow | 60 | 3 | 1 | No | Yes |
| 15863076 | PATTERNED DOSING OF IMMUNOSUPPRESSANTS COUPLED TO SYNTHETIC NANOCARRIERS | January 2018 | December 2024 | Abandon | 60 | 7 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SALVOZA, M FRANCO G.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SALVOZA, M FRANCO G works in Art Unit 1671 and has examined 25 patent applications in our dataset. With an allowance rate of 60.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 49 months.
Examiner SALVOZA, M FRANCO G's allowance rate of 60.0% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SALVOZA, M FRANCO G receive 2.88 office actions before reaching final disposition. This places the examiner in the 84% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by SALVOZA, M FRANCO G is 49 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +25.0% benefit to allowance rate for applications examined by SALVOZA, M FRANCO G. This interview benefit is in the 72% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 20.4% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 25.0% of cases where such amendments are filed. This entry rate is in the 33% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.